Am I Depressed — or Is This Perimenopause? Understanding Mood Changes During the Transition
Perimenopausal depression often presents differently from depression at other life stages — with irritability and numbness, and with the hormonal transition as a specific biological driver. Distinguishing mood instability from clinical depression, and both from an undertreated perimenopausal transition, is one of the most consequential distinctions in midlife mental health care.
By Dr. Julie Rashkis, Psy.D. | Licensed Psychologist | Menopause Society Certified Practitioner | therapyformidlife.com
'I don't feel sad exactly. I feel flat. Like the color has been turned down on everything. Things I used to love don't do anything for me. I go through the motions. I'm fine — except that nothing feels fine.' She pauses. 'Is that depression? Or is it just menopause? And does it matter which one it is?'
It matters enormously. And not just for the obvious reason — that depression and perimenopausal mood instability have somewhat different treatment profiles. It matters because the assumption that they are the same thing, or that the distinction is unimportant, has led to countless women in their 40s and early 50s being given antidepressants alone for what is substantially a hormonal condition, while the hormonal condition goes unaddressed. Or conversely, being told that what they are experiencing is 'just perimenopause' when it has crossed into clinical depression requiring structured treatment. Getting this right is one of the most important things a clinician or a patient can do at this stage of life.
This article explains the spectrum of mood change that perimenopause produces — from expected mood instability to clinical depression — what distinguishes them, and what the research says about treating each appropriately.
The Spectrum: From Mood Instability to Major Depression
Not all mood changes during perimenopause are depression. The first and most important distinction is between perimenopausal mood instability — the volatile, fluctuating low moods, irritability, and emotional reactivity driven by hormonal disruption — and a clinical depressive episode, which meets diagnostic criteria for Major Depressive Disorder (MDD) and requires more targeted treatment.
Perimenopausal mood instability is extremely common. Research suggests more than half of all perimenopausal women report some increase in depressive symptoms. But having depressive symptoms is not the same as having MDD. Mood instability during the transition typically fluctuates with hormonal shifts — it comes and goes, often in relation to cycle changes or vasomotor symptom flares — and may improve significantly with hormonal stabilization alone.
Clinical MDD during perimenopause is also common — and more serious. The SWAN study found that women are 1.5 to 2 times more likely to experience a major depressive episode during perimenopause than during premenopause. The Penn Ovarian Aging Study found that perimenopause doubled the odds of a first depressive episode; for women with no prior history of depression, the risk of a first-onset MDD was significantly elevated. This is not mood instability. It is a clinical syndrome that, left untreated, increases risk for cardiovascular disease, sleep disorders, osteoporosis, and further psychiatric vulnerability.
"Untreated perimenopausal depression not only exacerbates the course of a depressive illness — it also puts women at increased risk for sleep disorders, cardiovascular disease, diabetes, and osteoporosis. The stakes of missing this diagnosis are not small." — Optimal Management of Perimenopausal Depression, PMC
How Perimenopausal Depression Presents: The Atypical Picture
One of the primary reasons perimenopausal depression gets missed is that it often does not look like the textbook presentation of MDD that clinicians — and patients — have been trained to recognize. Classic depression is characterized by persistent sadness, hopelessness, tearfulness, and a loss of interest in activities. Perimenopausal depression frequently presents differently.
Classic MDD presentation: Persistent sadness, tearfulness
Perimenopausal depression — common atypical features: Numbness, flatness, emotional blunting — 'I can't feel anything' rather than 'I feel terrible'
Classic MDD presentation: Hopelessness about the future
Perimenopausal depression — common atypical features: Irritability, anger, frustration — emotional volatility that reads as mood disorder rather than depression
Classic MDD presentation: Crying spells
Perimenopausal depression — common atypical features: Anhedonia as the primary feature — loss of joy, pleasure, or engagement without prominent sadness
Classic MDD presentation: Clear low mood most of the day
Perimenopausal depression — common atypical features: Fatigue, cognitive slowness, and low motivation that may be attributed to 'just aging' or stress
Classic MDD presentation: Difficulty getting out of bed
Perimenopausal depression — common atypical features: Functioning maintained externally (going to work, managing household) while internal life feels empty or meaningless
Classic MDD presentation: Identified as depression by patient
Perimenopausal depression — common atypical features: Patient may not self-identify as depressed; more likely to report 'I don't feel like myself' or 'something is off'
Research confirms that perimenopausal depression often presents with 'atypical features' — irritability rather than sadness, anhedonia (the loss of pleasure) as the predominant symptom, fatigue, and cognitive complaints. The NIH notes that rather than overt sadness, perimenopausal women with depression may report fatigue, irritability, or anhedonia — symptoms easily mistaken for 'normal' aging or stress. This atypical presentation is not merely an inconvenience; it is one of the primary drivers of underdetection and misdiagnosis.
The anhedonia question is worth pausing on. Anhedonia — the diminished ability to feel pleasure or interest in things that previously brought joy — is one of the two cardinal symptoms of MDD (alongside depressed mood) and can be present even when sadness is not. Many perimenopausal women describe exactly this: 'I don't feel sad. I just feel nothing. Things I used to look forward to — I can't find the interest. I don't know who I am without those things.' This is not malaise. This is a clinical symptom that should prompt careful assessment.
The Misdiagnosis Problem — and Its Consequences
Two distinct misdiagnosis patterns recur in perimenopausal mental health. Both have meaningful consequences.
Pattern one: the perimenopausal transition is missed and only depression is treated. A woman in her mid-40s presents with low mood, irritability, difficulty sleeping, and loss of enjoyment. She is assessed for depression, meets criteria for MDD, and is prescribed an antidepressant. What is not asked is whether her menstrual cycle has changed, whether she has vasomotor symptoms, and whether there is a hormonal driver underlying her depressive episode. The antidepressant may provide partial relief. But the perimenopausal contribution to her depression — the estrogen fluctuations disrupting serotonin regulation, the sleep disruption amplifying mood vulnerability, the allopregnanolone deficit reducing her capacity for calm — remains unaddressed. She continues to struggle and concludes, often with shame, that she is 'medication resistant.'
Pattern two: clinical depression is attributed entirely to perimenopause and goes untreated. A woman is told by a well-meaning clinician that what she is experiencing is 'just perimenopause' and will pass. She is not assessed for MDD. She does not receive structured treatment. Weeks become months. Untreated depression lengthens, deepens, and increases the risk of recurrence. The research is clear that untreated depression during perimenopause is not benign.
A third pattern deserves mention: the antidepressant response problem. Research has documented that peri- and postmenopausal women do not respond to selective serotonin reuptake inhibitors (SSRIs) as reliably as other demographics. An older study by Kornstein and colleagues found that younger women showed more robust response to SSRIs than older women, and that this difference was linked to menopausal status. The implication is that a perimenopausal woman who does not respond to an SSRI is not necessarily treatment-resistant — she may be hormonally undertreated, and adding estradiol to the
treatment regimen may produce the response the antidepressant alone could not.
What Distinguishes Perimenopausal Mood Instability from Clinical MDD
Several clinical markers help distinguish perimenopausal mood instability from MDD, though the two frequently co-exist and both may require treatment:
Duration and persistence. Mood instability associated with perimenopause tends to fluctuate — it worsens in certain hormonal phases, improves in others, and does not typically persist at the same intensity every day for weeks. MDD requires that symptoms be present most of the day, nearly every day, for at least two weeks. A woman who has good days and bad days, with moods that seem to track hormonal shifts, is more likely to be experiencing perimenopausal mood instability than a constant clinical episode.
The relationship between mood and hormonal events. Does mood worsen around the time of irregular periods, hot flashes, or poor sleep? Does it improve when vasomotor symptoms are better managed? This relationship between mood and hormonal context is a significant clinical marker of perimenopausal mood instability.
Anhedonia versus reactivity. Perimenopausal mood instability tends to be reactive — moods fluctuate in response to circumstances and hormonal state. Clinical depression tends to involve a more fixed anhedonia — a baseline reduction in the capacity for pleasure that does not lift with good news or positive events. If a woman says 'nothing feels enjoyable anymore, even on good days,' that warrants depression assessment beyond hormonal evaluation.
Functional impairment. Both mood instability and MDD can impair functioning, but MDD typically produces more pervasive impairment across multiple domains — work performance, relationships, self-care, and motivation — that does not resolve with a good night's sleep or a less symptomatic week.
Prior reproductive mood history. Women with a history of PMDD, postpartum depression, or mood sensitivity to hormonal contraceptives are at significantly elevated risk for perimenopausal depression and may experience a more complex clinical picture where mood instability and MDD are intertwined. This history should be among the first questions asked.
What Treatment Should Actually Include
Optimal treatment of depression during perimenopause is inherently biopsychosocial. The research supports an integrated approach that addresses the hormonal, psychological, and behavioral dimensions simultaneously rather than sequentially.
For new-onset low mood without significant prior psychiatric history and without suicidality, guidelines support considering hormonal stabilization as a first-line intervention, either alone or alongside psychotherapy. Estradiol therapy has been shown to benefit women with first-onset perimenopausal depression, and the combination of hormone therapy with antidepressants shows greater effectiveness than antidepressants alone in several studies. The hormonal context should be part of any treatment conversation — ideally in coordination between a menopause-specialized medical provider and a psychologist or therapist.
For moderate to severe MDD, for recurrent depression, and for women with suicidality, antidepressant treatment is a clinical standard — though the choice of agent matters. The hormonal context should inform medication selection.
Psychotherapy occupies a distinct and irreplaceable role in this picture. Therapy does not merely address symptoms — it addresses the meaning of the experience, the accumulated weight of change and loss that the perimenopausal transition can carry, the identity questions the transition raises, and the relational impact of mood changes on partnerships and family systems. Cognitive Behavioral Therapy has a strong evidence base for perimenopausal depression. Acceptance and Commitment Therapy (ACT) is particularly well-suited to the identity and meaning dimensions of the transition. And for women whose mood changes are embedded in relational or trauma history, deeper psychological work is often necessary alongside any medical intervention.
Sleep is not a sidebar. Research has consistently found that treating the sleep disruption of perimenopause — through CBT-I, through hormonal stabilization, through behavioral sleep hygiene — produces downstream improvements in mood that are not achievable through mood-targeted interventions alone.
When to Seek Help
The Menopause Society recommends that if you experience symptoms of depression or a loss of pleasure in things you usually enjoy, nearly every day, for at least two weeks, those symptoms warrant evaluation — not minimization, and not waiting for menopause to resolve them. Depression during perimenopause is treatable. It does not have to be survived.
Specific circumstances warrant prompt clinical attention: any experience of suicidal thinking or self-harm ideation; mood changes that significantly impair functioning at work, in relationships, or in daily self-care; symptoms that are not responding to hormonal treatment alone; and depression in women with a prior history of MDD who are entering perimenopause, as they are at elevated risk for recurrence.
The question 'am I depressed or is this perimenopause?' is not always a binary. For many women in their 40s, the honest clinical answer is: both — and each dimension deserves its own treatment. The most important step is not resolving the question alone, but bringing it to a clinician who understands both.
About the Author
Dr. Julie Rashkis is a licensed psychologist and Menopause Society Certified Practitioner with over 20 years of clinical experience. She specializes in the psychological dimensions of perimenopause, menopause, and midlife transitions — working at the biopsychosocial intersection where hormonal health and mental health meet. She is the founder of Therapy for Midlife, a virtual practice licensed in California and Wisconsin, seeing clients across all PSYPACT-participating states.
www.therapyformidlife.com | Book a free consultation
References
1. Bromberger, J. T., et al. (2011). Mood and menopause: Findings from SWAN over 10 years. Obstetrics and Gynecology Clinics of North America, 38(3), 609-625. PMC3197240.
2. Freeman, E. W., et al. (2006). Associations of hormones and menopausal status with depressed mood in women with no history of depression. Archives of General Psychiatry, 63(4), 375-382. [Penn Ovarian Aging Study]
3. Bromberger, J. T., & Epperson, C. N. (2018). Depression during and after the perimenopause: Impact of hormones, sleep, and menopause symptoms. Obstetrics and Gynecology Clinics of North America, 45(4), 663-678. PMC6226029. 4. Herson, M., & Kulkarni, J. (2018). Perimenopausal depression — an under-recognised entity. Australian Prescriber, 41(6), 183-185. PMC6299176.
5. Gordon, J. L., & Girdler, S. S. (2014). Mechanisms underlying hemodynamic and neuroendocrine stress reactivity at different phases of the menopausal transition. Journal of Psychosomatic Research, 76(1), 1-7.
6. Kornstein, S. G., et al. (2000). Gender differences in treatment response to sertraline versus imipramine in chronic depression. American Journal of Psychiatry, 157(9), 1445-1452.
7. Soares, C. N., et al. (2001). Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women. Archives of General Psychiatry, 58(6), 529-534.
8. Kulkarni, J., et al. (2018). Development and validation of a new rating scale for perimenopausal depression — the Meno-D. Translational Psychiatry, 8, 123.
9. The Menopause Charity. (2024). Antidepressants and menopause. themenopausecharity.org.
10. PMC. (2025). Menopause and mental health. PMC12237151.
11. Joffe, H., & Cohen, L. S. (2019). Perimenopause and first-onset mood disorders: A closer look. FOCUS: The Journal of Lifelong Learning in Psychiatry.
